drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (TCR-T)
drug_description
Engineered TCR T-cell therapy targeting MAGE-A4; autologous T cells transduced to express a T-cell receptor recognizing MAGE-A4 peptide–HLA complexes on tumor cells.
nci_thesaurus_concept_id
C175738
nci_thesaurus_preferred_term
Afamitresgene Autoleucel
nci_thesaurus_definition
A preparation of autologous human T-lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen (TAA) MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types.
drug_mesh_term
Adoptive Immunotherapy
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are transduced to express an affinity‑enhanced T‑cell receptor specific for an HLA‑A2–restricted MAGE‑A4 peptide. After infusion, these TCR‑T cells recognize the peptide–HLA complex on tumor cells, activate, and kill MAGE‑A4–expressing cancer cells via cytotoxic mechanisms (e.g., perforin/granzyme).
drug_name
Afamitresgene autoleucel
nct_id_drug_ref
NCT06113315